Crossmark

Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD)

Crossref DOI link: https://doi.org/10.1007/s00210-025-03789-6

Published Online: 2025-01-17

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Selim, Dahshan Hassan

Mokhlis, Hamada Ahmed

Elsayed, Abdelrahman M.

Shatat, Abdel-Aziz S.

Salama, Salama Abdou

Ismail, Raed Shahat
Funding

Funding for this research was provided by:

Al-Azhar University
License Information

Text and Data Mining valid from 2025-01-17

Version of Record valid from 2025-01-17
More Information

Article History

Received: 24 November 2024

Accepted: 4 January 2025

First Online: 17 January 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below